Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples